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Abstract
Background: In 2011, Manitoba implemented a province-wide program of physician detailing and free sampling
for generic atorvastatin to increase use of this generic statin. We examined the impact of this unique combined
program of detailing and sampling for generic atorvastatin on the use and cost of statin medicines, market
share of generic atorvastatin, the choice of starting statin for new users, and switching from a branded statin
to generic atorvastatin.
Methods: We conducted a retrospective study of Manitoba insurance claims data for all continuously enrolled
patients who filled one or more prescriptions for a statin between 2008 and 2013. Data were linked to physician-level
data on the number of detailing visits and sample provision. We used interrupted time series analyses to assess
policy-related changes in the use and cost of statin medicines, market share of generic atorvastatin, the choice of
starting statin for new users, and switching from a branded statin to generic atorvastatin.
Results: The detailing program reached 31% (651/2103) of physicians who prescribed a statin during the study period.
Collectively, these physicians prescribed 61% of statins dispensed in the province. Free sample cards were provided to
61% (394/651) of the detailed physicians. The program did not change the level or trend in the overall statin use rate
and the total cost of statins or increase the number of patients switching from another branded statin to generic
atorvastatin. We found the program had a small impact on atorvastatin’s market share of new prescriptions, with a
level increase of 2.6%.
Conclusions: Though physician detailers were skilled at targeting high-prescribing physicians, a combined program of
detailing visits and sample provision for generic atorvastatin did not lower overall statin costs or lead to switching from
branded statins to the generic. The preceding introduction of generic atorvastatin appeared sufficient to modify
prescribing patterns and decrease costs.
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Background
Controlling prescription drug expenditures remains a
top priority for both public and private drug programs.
One important cost-saving opportunity is increasing
the use of cheaper (but therapeutically interchangeable)
generic alternatives [1]. In Canada, each province has
its own public drug plan and policies regarding generic
drugs. However, the use of generics is encouraged by all
Canadian provincial drug plans and some private drug
plans through some form of mandatory generic substi-
tution rules and interchangeability provisions that allow
generics to be dispensed instead of more expensive
brand-name alternatives [2]. As a result, generic drugs
represented 71.5% of all the prescriptions dispensed in
Canada in 2013 [3]. It is in the interest of insurers world-
wide to encourage switching to generic alternatives given
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the major potential for savings, especially as the avail-
ability of generic drugs continues to rise [4].
One commonly used and effective method to change
prescribing is “physician detailing”—the use of face-to-
face visits by sales representatives to promote the pre-
scribing of particular medicines [5, 6]. Most frequently,
methods are employed to increase the use of medicines
remaining under patent protection. However, many drug
programs have attempted to steer physicians toward pre-
scribing the most cost-effective agent using similar tac-
tics of face-to-face visits in the practice of academic
detailing, in order to improve both quality and cost ef-
fectiveness of care [7].
While the impact of academic detailing in isolation
has been well studied [8], there have been few rigorous
studies on the impact of providing samples on physician-
prescribing behavior. The small number of published
studies suggests that the availability of branded samples
increases prescribing of more expensive branded medica-
tions over more cost-effective and/or preferred medica-
tions [9–12]. Two observational studies suggest that
generic sampling programs on their own have a small or
limited impact on overall generic dispensing rates [13, 14].
To our knowledge, there has only been one study pairing
generic sampling with physician detailing that demon-
strated a 1.77% increase in the overall generic dispensing
rate over and above the impact of physician detailing
alone [15]. We are not aware of any studies that compare
a combined program of physician detailing and sampling
to the status quo (no intervention).
In 2011, Manitoba Health implemented an innovative
program aimed at increasing the use of generic atorva-
statin, a cholesterol-lowering statin medicine. At the
time, atorvastatin was the top-selling drug in the world
[16]. Many other drugs are also available within the statin
class (such as rosuvastatin, simvastatin, and fluvastatin)
and are therapeutically equivalent [17]. This program used
detailers who visited high-prescribing physicians to pro-
mote the use of generic atorvastatin, with the intent of en-
couraging new patients to start on generic atorvastatin
and established patients to switch to generic atorvastatin
from rosuvastatin, which at the time remained available
only as a more expensive branded drug. What differenti-
ated this program from conventional “academic detailing”
is that it included the distribution of cards that provided
free samples of generic atorvastatin to physicians. As there
are no rigorous data on the efficacy of a combined pro-
gram of detailing visits and sample provision on generic
drug use, we studied the impact of the program.
Methods
Study context
In 2011, Manitoba was the fifth-most populous province
in Canada, with a population of 1.2 million [18]. Manitoba
has a provincial Pharmacare program that covers all
Manitobans; however, drugs are only reimbursed after a
patient pays an annual deductible based on family income
[19]. In this system, prescription drugs are paid for by a
mix of public and private coverage, as well as out-of-
pocket by the patient.
The province of Manitoba granted an exclusive
listing on the public formulary to the generic manufac-
turer Ranbaxy for atorvastatin in June 2010 [20]. Reim-
bursement of the Ranbaxy version of atorvastatin
(Ran-Atorvastatin®) by the public plan began on
October 14, 2010. In exchange for this exclusive listing,
Ranbaxy initiated a program of physician detailing and
free sampling, which started in June 2011. Ranbaxy used a
private company specializing in the promotion of medi-
cines and recruited two staff members to detail physicians.
These representatives promoted the use of Ran-
Atorvastatin® to physicians that were high prescribers of
statins in the province and provided electronic cards that
patients could exchange at the pharmacy for a free 30-day
supply of Ran-Atorvastatin®. The program aimed to in-
crease Ran-Atorvastatin® prescribing while decreasing pre-
scribing of more expensive but therapeutically equivalent
branded atorvastatin and branded rosuvastatin. As a pri-
vate firm conducted these visits, we assumed that the de-
tailing methods employed were similar to those used for
detailing visits of other medicines. The intent was that
these representatives should detail physicians every 45 to
60 days, with a target to see each physician six to nine
times per year.
Data sources and study population
We conducted a retrospective study of Manitoba insur-
ance claims data for all continuously enrolled patients
who filled one or more prescriptions for a statin between
June 2008 and March 2013. This includes data from 2
years prior to generic atorvastatin being available on the
Manitoba Pharmacare formulary until 21 months fol-
lowing the implementation of the generic detailing and
sampling program. Based on prescriber information for
each statin prescription, we linked this insurance claims
data to physician-level information on the date of each
detailing visit and the number of sample cards provided
during each encounter.
This study used administrative data that includes
individual-level data on virtually all Manitobans con-
tained in the Population Health Research Data Repository,
which is housed at the Manitoba Centre for Health Policy
[21]. Four population-based, administrative data sources
were used in this analysis and linked using anonymous
identifiers: (1) prescription dispensation records from
outpatient dispensaries through Manitoba Health’s
Drug Programs Information Network, (2) Manitoba
Health Population Registry, (3) Manitoba Provider
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Registry (prescribers), and (4) records on the physician
detailing visits made to each physician.
Study cohorts
To study the impact of the detailing and sampling pro-
gram on particular groups, we constructed two sub-
cohorts of patients according to the following definitions:
1. Switching: “Switchers” received a prescription for a
statin after the receipt of two or more prescriptions
for a different statin (either a different brand or a
brand vs. generic) over the past year.
2. Starting: “Starters” received a prescription for a
statin after receiving no statin prescriptions in the
previous year [22].
Hypotheses
We hypothesized that the program would increase the
use of generic atorvastatin, decrease the use of other sta-
tins, and decrease total costs; that the policy would have
a greater impact on new starters than those switching
from a branded statin to generic atorvastatin; and that
the policy would promote more switching from branded
to generic atorvastatin than from branded rosuvastatin
to generic atorvastatin.
Statistical analysis
We used interrupted time series analysis to study longi-
tudinal changes in drug utilization and costs, the statins
which patients start on, and rates of switching [23]. This
method has the distinct advantages of being methodo-
logically rigorous and easily interpretable by non-technical
audiences while also controlling for pre-existing secular
trends in the outcome. It has been successfully used by
many previous pharmaceutical policy evaluations in
Canada [24–27]. Using interrupted time series analysis,
we were able to estimate the change in the level and the
trend of each outcome following the start of the detailing
and sampling policy. As the monthly observations were
correlated over time, we controlled for autocorrelation
using appropriate adjustments in a generalized least
squares model [23].
Our analyses used the following measures to deter-
mine the impact of the policy:
Prescription drug utilization Our analysis of drug
utilization focused on the number of prescriptions. In
this analysis, we examined whether the detailing and
sampling program increased the overall level of statin
prescribing in the province or led to changes between
different types of statins. For this analysis, we classified
drugs into six groups: (1) branded atorvastatin, (2) gen-
eric atorvastatin, (3) branded rosuvastatin, (4) generic
rosuvastatin, (5) other branded statins, and (6) other
generic statins. Branded drugs, such as Lipitor® in the case
of atorvastatin and Crestor® in the case of rosuvastatin, are
released by the company that originally developed and mar-
keted the medicine. Generics are drugs of the same mol-
ecule that come to market after patent protection expires.
Costs We examined the impact of the detailing program
on statin cost by studying the longitudinal change in
overall statin costs within the province.
Switching rate Among switchers, we examined longitu-
dinal changes in the proportion of patients that switched
from (1) branded atorvastatin to generic atorvastatin
and (2) branded rosuvastatin to generic atorvastatin.
Starting medication Amongst starters, we examined
longitudinal changes in the proportion of patients initi-
ated on each of the six types of statins.
Results
Program reach
The detailing program reached 31% (651/2103) of physi-
cians who prescribed a statin during the study period.
Collectively, these detailed physicians prescribed 61% of
statins dispensed in the province. Between June 2011
and February 2013, 5154 detailing visits were con-
ducted, with the average physician being visited 7.9
times (approximately once every 3 months). The maxi-
mum number of visits to one physician was 30. Free
sample cards were provided to 61% (394/651) of the de-
tailed physicians. Of those physicians provided with
sample cards, the median number of times sampled
(visits during which sample cards were provided) was two
and the maximum number of times sampled was 14.
Study cohort
There were 152,020 statin users in Manitoba with con-
tinuous coverage between 2008 and 2013 included in the
study. Of these users, 66,091 (43.4%) were new users
and 69,876 (46.0%) switched statins over the study
period. The age and sex of the study cohort, as well as
the new starter and switcher cohorts, are presented in
Table 1.
Overall statin prescribing
We observed that overall statin prescribing increased
steadily by 486 prescriptions per month over the study
period (95% CI 408 to 565, p < 0.01, Fig. 1). When gen-
eric atorvastatin became available, there was an almost
complete replacement of branded atorvastatin within a
few months. We observed a similar pattern for generic
rosuvastatin. However, neither the release of generic ator-
vastatin (level change of 732 prescriptions, 95% CI − 2223
to 3686, p = 0.28, trend change of − 40 prescriptions per
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month, 95% CI − 574 to 494, p = 0.74) nor the detailing
and sampling program (level change of 785 prescriptions,
95% CI − 1897 to 3467, p = 0.20, trend change of − 156
prescriptions per month, 95% CI − 695 to 384, p = 0.21)
had a significant impact on overall statin prescribing.
Overall statin costs
Total statin costs were rising at a rate of $34,884 per
month (95% CI 18,325 to 51,443, p < 0.01) before the
introduction of generic atorvastatin (Fig. 2). When gen-
eric atorvastatin was put on the Manitoba formulary,
there was a significant $1,096,543 drop in cost of statins
(95% CI − 1,720,604 to − 472,482, p < 0.01), though we
found no significant change in trend ($− 81,721 per
month, 95% CI − 194,527 to 31,086, p = 0.25). We
found no further changes in the level ($307,228, 95%
CI − 259,149 to 873,604, p = 0.32) or trend ($− 38,513
per month, 95% CI − 152,474 to 75,449, p = 0.60) of
statin costs after the implementation of the detailing
and sampling program.
Switchers
When generic atorvastatin was put on the Manitoba for-
mulary, 37,614 patients switched from branded atorva-
statin to generic atorvastatin in the 6 months following.
In contrast, we found no meaningful change in the
number of patients switching from either branded ator-
vastatin or branded rosuvastatin to generic atorvastatin
following the start of the detailing and sampling pro-
gram. This can be seen in Fig. 3.
Starters
Prior to the introduction of generic atorvastatin, ap-
proximately 1560 patients were newly started on statins
each month. As shown in Fig. 4, the introduction of
generic atorvastatin did not impact the level (1.3%, 95%
CI − 1.3 to 3.9%, p = 0.11) or trend (0.1% per month,
95% CI − 0.4 to 0.6%, p = 0.42) of atorvastatin’s share of
new statin prescriptions. We did find, however, that the
detailing and sampling program had a small impact on
atorvastatin’s market share of new prescriptions, with
an increase of 2.5% (95% CI 0.1 to 5.0%, p < 0.01).
Table 1 Age and sex of statin users, and new starter and switcher cohorts of statin users
Age ≤ 44 (%) 45–54 (%) 55–64 (%) 65–74 (%) 75+ (%) All ages
Users Female 5.2 15.6 28.8 25.2 25.2 70,535
Male 8.3 20.5 30.8 16.6 23.8 81,484
Starter Female 8.7 21.9 32.5 15.5 21.4 30,401
Male 13.2 26.7 30.8 10.3 19.0 35,690
Switcher Female 3.5 14.0 29.1 26.5 26.9 31,818
Male 5.7 18.7 32.2 17.8 25.6 38,058
Fig. 1 Statin prescribing in Manitoba from 2008 to 2013
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Overall, this change translates to approximately 126
more new atorvastatin users in the year following the
program than would have been expected based on
existing trends. There was no significant impact on the
trend of atorvastatin’s market share of new prescrip-
tions following the detailing and sampling program
(− 0.2% per month, 95% CI − 0.7 to 0.3%, p = 0.14).
Discussion
As a growing number of commonly prescribed drugs
lose patent protection, it is becoming increasingly im-
portant to promote the use of less expensive generic
medicines. Despite being run by a commercial detailing
firm and having successfully targeted high-prescribing
physicians, we found that the use of physician detailing
Fig. 2 Total cost of statins in Manitoba from 2008 to 2013
Fig. 3 Number of people who switched from a branded statin to generic atorvastatin from 2009 to 2013
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and sample provision in Manitoba did not meaningfully
impact either generic statin use or overall statin costs.
Importantly, we found the program did not promote
switching established users from branded rosuvastatin,
despite this being one of the main aims of the program.
Finally, while we did find an impact on the choice of
starting statin for new users, the size of this effect was
very small.
Our results run counter to a significant body of evi-
dence in support of academic detailing [7, 28–33] and
mounting evidence in support of sample provision in
modifying prescribing behavior [9–11]. We propose
two possible explanations for this discrepancy. First,
mandatory generic substitution rules and interchange-
ability provisions existed in Manitoba that required
pharmacists to dispense generics in place of equivalent
brand-name alternatives [34]. This means that even if a
physician prescribes the branded drug, unless the
physician has explicitly stated that there are to be no
substitutions, the pharmacy will dispense the generic
drug. As shown above, when generic atorvastatin be-
came available on the Manitoba formulary, there was
an almost complete replacement of branded atorva-
statin within a few months prior to the detailing and
sampling program. These mandatory substitution poli-
cies are very effective and do not seem to have any ob-
vious harms [35]. Second, despite one of the program’s
stated aims being to encourage switching from branded
rosuvastatin to generic atorvastatin, there is very little
evidence to suggest that this was an achievable goal.
There have been many studies indicating physician’s
reluctance to change an effective treatment [36]. Therefore,
if a patient’s cholesterol was being well managed on
branded rosuvastatin, a physician was unlikely to switch
them to a different drug despite evidence of similar efficacy.
The comparatively small impact on the choice of starting
drug may have been influenced by either detailing on the
part of rosuvastatin’s manufacturer or by the knowledge
physicians may have had about rosuvastatin’s pending pa-
tent expiration. The data available only allowed us to evalu-
ate the reach, fidelity, and dose of the program, but we
were unable to evaluate these contextual factors that may
have shaped how the intervention functioned [37].
While this study was designed to exploit the natural
experiment created by the implementation of the policy,
there are several limitations to our work. As our study
used administrative health data, we could not examine
detailed clinical data that might be obtained through
medical records. Similarly, we had limited measures re-
garding the appropriateness of prescribing, patient satis-
faction, side effects, low-density lipoprotein levels, and
health outcomes for individuals who were started on one
statin versus another or were switched. However, much
of the available clinical evidence suggests that these
drugs have similar efficacy [38]. As the generic detailing
and sampling program in Manitoba was only conducted
for atorvastatin, our results may not be directly applic-
able to other medication classes or clinical areas. How-
ever, given the widespread prescribing of these medicines,
we believe our results are likely indicative of what would
occur with a similar program for other popular
medication classes.
Fig. 4 Percent market share of new statin prescriptions in Manitoba from 2009 to 2013
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Conclusions
In a strictly regulated environment that includes generic
substitution, simply releasing a low-cost generic drug
will influence new starters on the drug to be prescribed
the generic. Switches on the other hand tend to be more
refractory, and even well-designed and evidence-based
programs to accelerate these pharmaceutical policies
have no room to further increase starts and do not affect
switching.
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